{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:26:10Z","timestamp":1778905570648,"version":"3.51.4"},"reference-count":161,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Monoclonal antibodies (mAbs) have become a cornerstone in the treatment of follicular lymphoma (FL), offering highly specific therapeutic targeting that enhances efficacy while minimizing systemic toxicity. Their mechanisms of action include antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptotic signaling, effectively mediating malignant B-cell depletion. Anti-CD20 mAbs, such as rituximab and obinutuzumab, have significantly improved progression-free survival (PFS) and overall survival (OS), establishing immunochemotherapy as the standard of care for FL. However, the emergence of treatment resistance, often characterized by CD20 antigen downregulation or immune escape, has prompted the development of next-generation mAbs with enhanced effector functions. Bispecific antibodies (BsAbs), which simultaneously engage CD20-expressing tumor cells and CD3-positive cytotoxic T cells, have emerged as a novel immunotherapeutic strategy, redirecting T-cell activity to eliminate malignant B cells independently of major histocompatibility complex (MHC) antigen presentation. Additionally, antibody\u2013drug conjugates (ADCs) offer a targeted cytotoxic approach by delivering potent chemotherapeutic payloads directly to tumor cells while limiting off-target effects. The integration of mAbs with immune checkpoint inhibitors and immunomodulatory agents is further enhancing treatment outcomes by overcoming immunosuppressive mechanisms within the tumor microenvironment. Despite these advancements, challenges remain, including optimizing the treatment sequence, mitigating immune-related toxicities\u2014particularly cytokine release syndrome (CRS)\u2014and identifying predictive biomarkers to guide patient selection. As the role of monoclonal antibodies continues to expand, their integration into therapeutic regimens is transforming the management of FL, paving the way for chemotherapy-free treatment approaches and long-term disease control. This review provides an updated overview of mAbs therapies for FL, emphasizing the advances brought by BsAbs and ADCs toward more tailored and effective treatments.<\/jats:p>","DOI":"10.3390\/cancers17101602","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T11:37:02Z","timestamp":1746704222000},"page":"1602","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Single-Agent and Associated Therapies with Monoclonal Antibodies: What About Follicular Lymphoma?"],"prefix":"10.3390","volume":"17","author":[{"given":"Gabriella","family":"Cancemi","sequence":"first","affiliation":[{"name":"Hematology Unit, Oncology-Hematology Department, Azienda Ospedaliera Papardo, 98158 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Campo","sequence":"additional","affiliation":[{"name":"Hematology Unit, Oncology-Hematology Department, Azienda Ospedaliera Papardo, 98158 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0698-1781","authenticated-orcid":false,"given":"Santino","family":"Caserta","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Human Pathology in Adulthood and Childhood \u201cGaetano Barresi\u201d, University of Messina, Via Consolare Valeria, 98125 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iolanda","family":"Rizzotti","sequence":"additional","affiliation":[{"name":"Hematology Unit, Oncology-Hematology Department, Azienda Ospedaliera Papardo, 98158 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8665-1258","authenticated-orcid":false,"given":"Donato","family":"Mannina","sequence":"additional","affiliation":[{"name":"Hematology Unit, Oncology-Hematology Department, Azienda Ospedaliera Papardo, 98158 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/978-1-0716-4442-3_18","article-title":"Generation and Reactivity Profiling of Functional Human Recombinant Monoclonal Antibodies","volume":"2909","author":"Iatrou","year":"2025","journal-title":"Methods Mol. Biol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Naman, J., Shah, N., and Heyman, B.M. (2025). Antibody Therapy for Patients with Lymphoid Malignancies: Past and Present. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26041711"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Sun, L., and Romancik, J.T. (2025). The Development and Application of Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma. J. Pers. Med., 15.","DOI":"10.3390\/jpm15020051"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Bayly-McCredie, E., Treisman, M., and Fiorenza, S. (2024). Safety and Efficacy of Bispecific Antibodies in Adults with Large B-Cell Lymphomas: A Systematic Review of Clinical Trial Data. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25179736"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1182\/bloodadvances.2024012916","article-title":"Infections in patients with lymphoma treated with bispecific antibodies: A systematic review and meta-analysis","volume":"8","author":"Reynolds","year":"2024","journal-title":"Blood Adv."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/ejh.13271","article-title":"Diagnosis and management of follicular lymphoma: A comprehensive review","volume":"103","author":"Dada","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Paul, S., and Zhou, S. (2025). Six events that shaped antibody approvals in oncology. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1533796"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e1103","DOI":"10.1002\/jha2.1103","article-title":"Immune Signatures Identify Patient Subsets Deriving Long-Term Benefit From First-Line Rituximab in Follicular Lymphoma","volume":"6","author":"Lolli","year":"2025","journal-title":"EJHaem"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Belviso, B.D., Mangiatordi, G.F., Alberga, D., Mangini, V., Carrozzini, B., and Caliandro, R. (2022). Structural Characterization of the Full-Length Anti-CD20 Antibody Rituximab. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.823174"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Azevedo, P.S., Zuppo Laper, I., Oliveira, D.M.D.S., Sabino, A.P., Garcia, M.M., de Freitas, I.C.M., Prata, W.M., Cherchiglia, M.L., \u00c1lvares-Teodoro, J., and Acurcio, F.A. (2025). Survival analysis of a 16-year cohort of follicular lymphoma patients receiving systemic treatment in Brazil. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1414244"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.annemergmed.2024.10.015","article-title":"Antibody-Drug Conjugates: The Toxicities and Adverse Effects That Emergency Physicians Must Know","volume":"85","author":"Markides","year":"2025","journal-title":"Ann. Emerg. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Shi, Y., Yao, K., Zhao, J., Yue, Y., and Wu, H. (2025). Gastrointestinal toxicity of antibody-drug conjugates: A pharmacovigilance study using the FAERS database. BMC Pharmacol. Toxicol., 26.","DOI":"10.1186\/s40360-025-00877-4"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Knabe, R., Muller, P., Schliemann, C., Hanoun, M., Unglaub, J.M., Weinbergerov\u00e1, B., Mayer, J., Krekeler, C., Krause, S.W., and Kaufmann, M. (2025). Gastrointestinal toxicity of Gemtuzumab Ozogamicin: Real-life data from the AMLCG, SAL and CELL study groups. Blood Adv., ahead of print.","DOI":"10.1182\/bloodadvances.2024014570"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Mosallam, G., Winer, E.S., Keating, J.H., Flamand, Y., and Solodokin, L.J. (2025). Utility of ursodiol prophylaxis against sinusoidal obstruction syndrome (SOS)\/veno-occlusive disease (VOD) in acute leukemia patients receiving gemtuzumab-ozogamicin (GO) or inotuzumab-ozogamicin (InO). J. Oncol. Pharm. Pract., ahead of print.","DOI":"10.1177\/10781552241313473"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Le, X., Zhang, Y., and Ma, J. (2025). Comprehensive analysis of adverse events associated with T-cell engagers using the FAERS database. Expert. Opin. Drug Saf., 1\u201310. ahead of print.","DOI":"10.1080\/14740338.2025.2470875"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"In, H., Park, M., Lee, H., and Han, K.H. (2025). Immune Cell Engagers: Advancing Precision Immunotherapy for Cancer Treatment. Antibodies, 14.","DOI":"10.3390\/antib14010016"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"100603","DOI":"10.1016\/j.medj.2025.100603","article-title":"Always more immunotherapy in the management of B-lineage acute lymphoblastic leukemia","volume":"6","year":"2025","journal-title":"Med"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/10428194.2021.1975188","article-title":"Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: Population-level projections for 2020\u20132025","volume":"63","author":"Kanas","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/leu.2014.251","article-title":"Follicular lymphoma in Sweden: Nationwide improved survival in the rituximab era, particularly in elderly women: A Swedish Lymphoma Registry study","volume":"29","author":"Peterson","year":"2015","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/hon.2601","article-title":"Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group","volume":"37","author":"Torrente","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","article-title":"Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma","volume":"25","author":"Montoto","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Enemark, M.H., Hemmingsen, J.K., Jensen, M.L., Kridel, R., and Ludvigsen, M. (2024). Molecular biomarkers in prediction of high-grade transformation and outcome in patients with follicular lymphoma: A comprehensive systemic review. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252011179"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.6093263","article-title":"Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation","volume":"226","author":"Tsujimoto","year":"1984","journal-title":"Science"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1182\/blood-2015-06-649905","article-title":"Cell of origin of transformed follicular lymphoma","volume":"126","author":"Kridel","year":"2015","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1182\/blood-2017-08-737361","article-title":"Chromatin modifying gene mutations in follicular lymphoma","volume":"131","author":"Green","year":"2018","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1182\/blood.2023020911","article-title":"Primary large B-cell lymphomas of immune-privileged sites","volume":"144","author":"Roschewski","year":"2024","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ajh.24937","article-title":"Follicular lymphoma: 2018 update on diagnosis and management","volume":"93","author":"Freedman","year":"2018","journal-title":"Am. J. ematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1517\/17530059.2012.686996","article-title":"Risk Factors of Follicular Lymphoma","volume":"6","author":"Ma","year":"2012","journal-title":"Expert. Opin. Med. Diagn."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4274\/tjh.galenos.2024.2024.0015","article-title":"Advancements in the Management of Follicular Lymphoma: A Comprehensive Review","volume":"41","author":"Merryman","year":"2024","journal-title":"Turk. J. Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.21.01234","article-title":"Fondazione Italiana Linfomi. Response-adapted postinduction strategy in patients with advanced-stage follicular lymphoma: The FOLL12 study","volume":"40","author":"Luminari","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.3324\/haematol.2021.279351","article-title":"Follicular lymphoma grade 3B and diffuse large B-cell lymphoma present a histopathological and molecular continuum lacking features of progression\/transformation","volume":"107","author":"Koch","year":"2022","journal-title":"Haematologica"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1097\/PAS.0000000000001726","article-title":"Lymphoma Study Association (LYSA). High-grade follicular lymphomas exhibit clinicopathologic, cytogenetic, and molecular diversity extending beyond grades 3A and 3B","volume":"45","author":"Laurent","year":"2021","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3390\/hemato3040042","article-title":"Genetics of Transformed Follicular Lymphoma","volume":"3","author":"Alcoceba","year":"2022","journal-title":"Hemato"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Kridel, R., Chan, F.C., Mottok, A., Boyle, M., Farinha, P., Tan, K., Meissner, B., Bashashati, A., McPherson, A., and Roth, A. (2016). Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study. PLoS Med., 13.","DOI":"10.1371\/journal.pmed.1002197"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/(SICI)1096-9896(199606)179:2<145::AID-PATH565>3.0.CO;2-1","article-title":"BCL-6 expression in reactive lymphoid tissue and in B-cell non-Hodgkin\u2019s lymphomas","volume":"179","author":"Pittaluga","year":"1996","journal-title":"J. Pathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/10428190701742472","article-title":"Frequency of BCL2 and BCL6 translocations in follicular lymphoma: Relation with histological and clinical features","volume":"49","author":"Doval","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.hoc.2020.02.001","article-title":"Epidemiology of Follicular Lymphoma","volume":"34","author":"Cerhan","year":"2020","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/2643-3230.BCD-21-0075","article-title":"Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression","volume":"3","author":"Han","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1200\/JCO.2018.79.3083","article-title":"Progress in Advanced-Stage Follicular Lymphoma","volume":"36","author":"Friedberg","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/hon.3138","article-title":"Update on follicular lymphoma","volume":"41","author":"Friedberg","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1200\/JCO.2009.26.1693","article-title":"Prognostic factors in follicular lymphoma","volume":"28","author":"Relander","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Roy","year":"2004","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: A new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/annonc\/mds429","article-title":"Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): A prospective US patient cohort treated predominantly in community practices","volume":"24","author":"Nooka","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: A retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s00259-010-1539-5","article-title":"Diagnostic and prognostic impact of 18F-FDG PET\/CT in follicular lymphoma","volume":"37","author":"Bayat","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.2012.43.0934","article-title":"Impact of [18F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: A prospective study from the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte and GOELAMS","volume":"30","author":"Dupuis","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/annonc\/mdt562","article-title":"The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL)","volume":"25","author":"Luminari","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1182\/blood.2021013437","article-title":"POD24 in follicular lymphoma: Time to be \u201cwise\u201d","volume":"139","author":"Leonard","year":"2022","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood.2020010263","article-title":"Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials","volume":"139","author":"Casulo","year":"2022","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1470-2045(14)70036-1","article-title":"4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): A randomised phase 3 non-inferiority trial","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2005.08.010","article-title":"Long-term outcome and mortality trends in early-stage, Grade 1\u20132 follicular lymphoma treated with radiation therapy","volume":"64","author":"Guadagnolo","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1200\/JCO.2004.10.086","article-title":"Stage I and II follicular non-Hodgkin\u2019s lymphoma: Long-term follow-up of no initial therapy","volume":"22","author":"Advani","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e499","DOI":"10.1016\/S2352-3026(24)00143-1","article-title":"Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): Final results of a prospective, multicentre, phase 2 trial","volume":"11","author":"Pulsoni","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: A randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: An open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1200\/JCO.2017.35.15_suppl.7501","article-title":"Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study","volume":"35","author":"Rummel","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: The Stanford University experience","volume":"122","author":"Tan","year":"2013","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi","volume":"31","author":"Federico","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the First-Line Treatment of Follicular Lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.2012.42.4101","article-title":"Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016","volume":"31","author":"Press","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1200\/JCO.23.01912","article-title":"Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low-Tumor Burden Follicular Lymphoma","volume":"42","author":"Kahl","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/bjh.13021","article-title":"90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease","volume":"167","author":"Samaniego","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(18)30618-1","article-title":"Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): Secondary analysis of a randomised, phase 3 trial","volume":"19","author":"Trotman","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood.2019000258","article-title":"Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma","volume":"134","author":"Freeman","year":"2019","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2017.76.3656","article-title":"Overall Survival Benefit in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study","volume":"36","author":"Cheson","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin\u2019s lymphoma: Long-term outcome of the EORTC 20981 phase III randomized intergroup study","volume":"28","author":"Giurgea","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/annonc\/mdw124","article-title":"Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: An analysis from the Lymphoma Working Party of the EBMT\u2020","volume":"27","author":"Robinson","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.bbmt.2017.12.771","article-title":"Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis","volume":"24","author":"Casulo","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.bbmt.2018.03.022","article-title":"Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group","volume":"24","author":"Jurinovic","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: An open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","article-title":"Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients with Refractory Indolent Non-Hodgkin Lymphoma","volume":"37","author":"Flinn","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: An open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Radhakrishnan, V.S., and Davies, A.J. (2024). Bispecific antibodies in indolent B-cell lymphomas. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1295599"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): A phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtageneciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): A single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: The phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.30156","article-title":"Rituximab: Mechanism of action and resistance","volume":"29","author":"Maloney","year":"2002","journal-title":"Semin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: Mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin. Hematol."},{"key":"ref_97","first-page":"676","article-title":"Mechanisms of action of CD20 antibodies","volume":"2","author":"Boross","year":"2012","journal-title":"Am. J. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma","volume":"84","author":"Maloney","year":"1994","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","article-title":"Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin\u2019s lymphoma","volume":"9","author":"Berinstein","year":"1998","journal-title":"Ann. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/01.ftd.0000184162.60197.c1","article-title":"Pharmacokinetic behavior of rituximab: A study of different schedules of administration for heterogeneous clinical settings","volume":"27","author":"Regazzi","year":"2005","journal-title":"Ther. Drug Monit."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/annonc\/mdh176","article-title":"IDEC-C2B8 Japan Study Group. Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma","volume":"15","author":"Tobinai","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","article-title":"ESMO Guidelines Committee. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Dreyling","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1200\/JCO.2004.04.020","article-title":"Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin\u2019s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up","volume":"22","author":"Czuczman","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.2012.082412","article-title":"Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA). Long-term follow-up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma","volume":"98","author":"Bachy","year":"2013","journal-title":"Haematologica"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ejca.2017.01.021","article-title":"Rituximab maintenance improves overall survival of patients with follicular lymphoma\u2014Individual patient data meta-analysis","volume":"76","author":"Vidal","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/1744666X.2019.1562905","article-title":"Infusion-related reactions to rituximab: Frequency, mechanisms, and predictors","volume":"15","author":"Paul","year":"2019","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/phar.2340","article-title":"Hepatitis B virus reactivation: Risk factors and current management strategies","volume":"39","author":"Smalls","year":"2019","journal-title":"Pharmacotherapy"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11926-021-01037-3","article-title":"Long-term safety of rituximab (risks of viral and opportunistic infections)","volume":"23","author":"Varley","year":"2021","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ijid.2020.11.194","article-title":"A rare urinary JC virus reactivation after long-term therapy with rituximab","volume":"103","author":"Viola","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000337577","article-title":"Rituximab and cytokine release syndrome","volume":"5","author":"Kulkarni","year":"2012","journal-title":"Case Rep. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"Moser","year":"2010","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood-2010-09-305847","article-title":"Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I\/II distinction of CD20 antibodies","volume":"118","author":"Niederfellner","year":"2011","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"Klein","year":"2013","journal-title":"MAbs"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","article-title":"Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models","volume":"12","author":"Herter","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1200\/JCO.2012.46.9718","article-title":"Obinutuzumab (GA101) in patients with relapsed\/refractory indolent non-Hodgkin lymphoma: Results from the phase II GAUGUIN study","volume":"31","author":"Salles","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3324\/haematol.2015.133421","article-title":"Rationale for optimal obinutuzumab\/GA101 dosing regimen in B-cell non-Hodgkin lymphoma","volume":"101","author":"Cartron","year":"2016","journal-title":"Haematologica"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"FSO375","DOI":"10.4155\/fsoa-2018-0122","article-title":"GALLIUM trial: The tortoise (rituximab) and the hare (obinutuzumab) race","volume":"5","author":"Peralta","year":"2019","journal-title":"Future Sci. OA"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2012-01-404368","article-title":"Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients","volume":"119","author":"Salles","year":"2012","journal-title":"Blood"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1177\/0091270009337512","article-title":"Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials","volume":"49","author":"Wang","year":"2009","journal-title":"J. Clin. Pharmacol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): A randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.1182\/blood-2012-02-408773","article-title":"A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies","volume":"119","author":"Sehn","year":"2012","journal-title":"Blood"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1200\/JCO.2014.59.2139","article-title":"Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: Final analysis of the GAUSS study","volume":"33","author":"Sehn","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/blood-2013-01-481341","article-title":"Obinutuzumab (GA101) plus CHOP or FC in relapsed\/refractory follicular lymphoma: Results of the GAUDI study (BO21000)","volume":"122","author":"Radford","year":"2013","journal-title":"Blood"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3324\/haematol.2016.152272","article-title":"Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma","volume":"102","author":"Grigg","year":"2017","journal-title":"Haematologica"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00277-016-2878-5","article-title":"Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone","volume":"96","author":"Cheson","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"6484","DOI":"10.3748\/wjg.v22.i28.6484","article-title":"Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy","volume":"22","author":"Law","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1080\/14740338.2016.1198775","article-title":"Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA\u2019s adverse event reporting system","volume":"15","author":"Raisch","year":"2016","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"287ra70","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s40262-016-0405-4","article-title":"Blinatumomab, a bispecific T-cell engager (BiTE\u00ae) for CD-19 targeted cancer immunotherapy: Clinical pharmacology and its implications","volume":"55","author":"Zhu","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/protein\/9.7.617","article-title":"\u2018Knobs-into-holes\u2019 engineering of antibody CH3 domains for heavy chain heterodimerization","volume":"9","author":"Ridgway","year":"1996","journal-title":"Protein Eng."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Hosseini, I., Gadkar, K., Stefanich, E., Li, C.C., Sun, L.L., Chu, Y.W., and Ramanujan, S. (2020). Mitigating the risk of cytokine release syndrome in a phase I trial of CD20\/CD3 bispecific antibody mosunetuzumab in NHL: Impact of translational system modeling. NPJ Syst. Biol. Appl., 6.","DOI":"10.1038\/s41540-020-00145-7"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: Phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40265-022-01749-5","article-title":"Mosunetuzumab: First approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1200\/JCO.20.03433","article-title":"Umbralisib, a dual PI3K\u03b4\/CK1\u03b5 inhibitor in patients with relapsed or refractory indolent lymphoma","volume":"39","author":"Fowler","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Bisio, M., Legato, L., Fasano, F., Benevolo Savelli, C., Boccomini, C., Nicolosi, M., Santambrogio, E., Freilone, R., Novo, M., and Botto, B. (2024). Bispecificantibodies for lymphoidmalignancy treatment. Cancers, 17.","DOI":"10.3390\/cancers17010094"},{"key":"ref_141","first-page":"1269","article-title":"Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma","volume":"109","author":"Song","year":"2024","journal-title":"Haematologica"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jtct.2023.12.050","article-title":"Deep and durable responses with epcoritamab SC monotherapy in patients with relapsed or refractory follicular lymphoma: Data from the Epcore NHL-1 follicular lymphoma dose-expansion cohort","volume":"30","author":"Linton","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.annonc.2024.08.2239","article-title":"ELM-2 Investigators. Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma","volume":"35","author":"Kim","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/01.HS9.0000847280.69256.81","article-title":"P1103: INMIND: A Phase 3 study of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab for relapsed\/refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL)","volume":"6","author":"Sehn","year":"2022","journal-title":"Hemasphere"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"LBA-1","DOI":"10.1182\/blood-2024-212970","article-title":"Tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Results from a Phase 3 study (inMIND)","volume":"144","author":"Sehn","year":"2024","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/hon.3166_OT29","article-title":"LOTIS-5, an ongoing Phase 3 randomized study of loncastuximabtesirine with rituximab (LONCA-R) versus immunochemotherapy in patients with R\/R DLBCL","volume":"41","author":"Kwiatek","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40265-023-01894-5","article-title":"Glofitamab: First approval","volume":"83","author":"Shirley","year":"2023","journal-title":"Drugs"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/bloodadvances.2023011089","article-title":"Predictive model for the risk of cytokine release syndrome with glofitamab treatment for diffuse large B-cell lymphoma","volume":"8","author":"Gritti","year":"2024","journal-title":"Blood Adv."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Li, T., Gibiansky, L., Parikh, A., Putnins, M., Chiu, C.W., Sacchi, M., Feng, H., Ahmadi, T., Gupta, M., and Xu, S. (2025). Optimal dosing regimen for epcoritamab, a subcutaneous bispecific antibody, in relapsed or refractory large B-cell lymphoma. Clin. Pharmacol. Ther., ahead of print.","DOI":"10.1002\/cpt.3588"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"4411","DOI":"10.1182\/blood-2024-200080","article-title":"Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the Phase 3 Olympia-1 Study","volume":"144","author":"Brem","year":"2024","journal-title":"Blood"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood-2023-179818","article-title":"Final analysis of the Phase 2 ELM-2 study: Odronextamab in patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL)","volume":"142","author":"Ayyappan","year":"2023","journal-title":"Blood"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1182\/blood-2024-200770","article-title":"Trial in progress: Odronextamab for the treatment of patients with relapsed\/refractory mantle cell lymphoma following prior BTK inhibitor therapy\u2014A cohort of the ELM-2 study","volume":"144","author":"Cho","year":"2024","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Topp, M.S., Matasar, M.J., Allan, J.N., Ansell, S.M., Barnes, J.A., Arnason, J.E., Michot, J.M., Goldschmidt, N., O\u2019Brien, S.M., and Abadi, U. (2024). Odronextamab monotherapy in R\/R DLBCL after progression with CAR T-cell therapy: Primary analysis of the ELM-1 study. Blood, ahead of print.","DOI":"10.1182\/blood.2024027044"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Jacobs, R., and Jacobson, C. (2024). The treatment of follicular lymphoma with CD19-directed chimeric antigen receptor T-cell therapy. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1384600"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/blood-2024-199093","article-title":"Loncastuximabtesirine with rituximab induces robust and durable complete metabolic responses in high-risk relapsed\/refractory follicular lymphoma","volume":"144","author":"Alderuccio","year":"2024","journal-title":"Blood"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S2352-3026(24)00345-4","article-title":"Loncastuximabtesirine with rituximab in patients with relapsed or refractory follicular lymphoma: A single-centre, single-arm, Phase 2 trial","volume":"12","author":"Alderuccio","year":"2025","journal-title":"Lancet Haematol."},{"key":"ref_157","first-page":"303","article-title":"The antibody-drug conjugateloncastuximabtesirine for the treatment of diffuse large B-cell lymphoma","volume":"140","author":"Calabretta","year":"2022","journal-title":"Blood"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1080\/10428190802090805","article-title":"How have outcomes for patients with follicular lymphoma changed with the addition of monoclonal antibodies?","volume":"49","author":"Illidge","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"100061","DOI":"10.1016\/j.bneo.2024.100061","article-title":"Safety landscape of bispecific antibody therapy in non-Hodgkin lymphoma: A meta-analysis","volume":"2","author":"Fonseca","year":"2025","journal-title":"Blood Neoplasia"},{"key":"ref_160","first-page":"97","article-title":"Follicular lymphoma: A focus on current and emerging therapies","volume":"36","author":"Cahill","year":"2022","journal-title":"Oncology"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s40164-024-00551-1","article-title":"Current and future therapies for follicular lymphoma","volume":"13","author":"Zinzani","year":"2024","journal-title":"Exp. Hematol. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/10\/1602\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:29:46Z","timestamp":1760030986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/10\/1602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":161,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["cancers17101602"],"URL":"https:\/\/doi.org\/10.3390\/cancers17101602","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]}}}